HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-29-2007, 04:38 PM   #1
harrie
Senior Member
 
harrie's Avatar
 
Join Date: Mar 2007
Location: Hilo, Hawaii
Posts: 1,867
Oncotype Dx

The recurrance score of the Oncotype DX, from my understanding, does not incorporate the HER2 elevation. Correct my if I am wrong. My Oncotype recurrance score was 20. (low intermediate)

Harrie
__________________
*** MARYANNE *** aka HARRIECANARIE

1993: right side DCIS, lumpectomy, rads
1999: left side DCIS, lumpectomy, rads, tamoxifen

2006:
BRCA 2 positive
Stage I, invasive DCIS (6mm x 5mm)
Grade: intermediate
sentinal node biopsy: neg
HER2/neu amplified 4.7
ER+/PR+
TOPO II neg
Oncotype dx 20
Bilat mastectomy with DIEP flap reconstruction
oophorectomy

2007:
6 cycles TCH (taxotere, carboplatin, herceptin)
finished 1 yr herceptin 05/07
Arimidex, stopped after almost 1 yr
Femara

Last edited by harrie; 03-29-2007 at 04:39 PM.. Reason: add info
harrie is offline   Reply With Quote
Old 03-29-2007, 06:08 PM   #2
Hopeful
Senior Member
 
Join Date: Aug 2006
Posts: 3,380
Harrie,

The Oncotype test does incorporate Her2; there is some debate about whether it weights it correctly (the debate being it is weighted too heavily rather than too lightly). I read one interview with Dr. Paik (the inventor of the test) where someone asked him about it directly, and he said he would have to look into it. Unfortunately, I didn't print out the page and have been searching for it again ever since. I know the trial that is designed around the use of the test to determine hormone therapy vs. chemo + hormone therapy is limited to Her2 negatives.

Hopeful
Hopeful is offline   Reply With Quote
Old 03-29-2007, 07:09 PM   #3
mjz
Member
 
Join Date: Mar 2007
Posts: 5
According to National Comprehensive Cancer Network guidelines limited data supports that a 21-gene assay (oncotypeDx)may provide both prognostic information and prediction of benefit, or lack therof, from chemo in node negative, hormone receptor-positive bc treated with tamoxifen. ---- this statement footnotes a flow chart for systemic adjuvant treatment-hormone responsive disease-HER-2/NEU overexpressed bc. My path along this flowchart (tumor 0.6-1.0 cm, moderately/poorly diffreentiated or unfavorable features) ends with"adjuvant hormonal therapy; WITH OR WITHOUT chemo. This is why I wonder and again hope that my score of 17 -the highest number still called "low risk" supports my decision to get herceptin without chemo... and wonder has anyone else used oncotype to help decide.
mjz is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 09:30 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter